Signal integration by JNK and p38 MAPK pathways in cancer development

Erwin F Wagner ¹, Angel R Nebreda

⁰Centro Nacional de Investigaciones Oncológicas, C/Melchor Fernández Almagro 3, Madrid 28029, Spain. ewagner@cnio.es

Nature Reviews. Cancer +

|

July 25, 2009

View abstract on PubMed

Summary

Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways are crucial in cancer development. Mouse models help elucidate their roles and inform new cancer therapies.

Area Of Science

Molecular Biology
Cell Signaling
Oncology

Background

Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways regulate cell proliferation, differentiation, survival, and migration.
Dysregulation of these signaling pathways is implicated in human and mouse cancers.
Understanding these pathways is critical for cancer research.

Purpose Of The Study

To review recent advancements in understanding the functions of JNK and p38 MAPK pathways in various cancers.
To highlight the importance of mouse models in cancer development research.
To explore potential therapeutic strategies based on MAPK signaling.

Main Methods

Literature review of recent studies on JNK and p38 MAPK signaling in cancer.
Analysis of data from mouse models investigating cancer development.
Synthesis of findings to define pathway functions in different cancer types.

Main Results

JNK and p38 MAPK pathways exhibit context- and cell type-specific functions in tumorigenesis.
Mouse models have been instrumental in revealing the intricate roles of these MAPKs in cancer.
Recent progress has clarified the involvement of these pathways across diverse cancers.

Conclusions

JNK and p38 MAPK signaling pathways are key regulators in cancer development.
Mouse models provide valuable insights for understanding cancer biology.
Further research into these pathways may lead to novel therapeutic interventions for cancer.

Related Concept Videos